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Abstract 
 
Mucin is a complex glycoprotein consisting of a wide variety of functional groups that can interact 
with exogenous agents. The binding to mucin plays a crucial role in drug pharmacokinetics especially 
in diseases, such as cystic fibrosis (CF), where mucin is overexpressed. In this study, we have 
investigated the interaction between mucin and several drugs used in CF therapy. Protein-drug 
interaction was carried out by UV-Vis and fluorescence spectroscopy; quenching mechanism, binding 
constants, number of binding sites, thermodynamic parameters and binding distance of the interaction 
were obtained.  
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1. INTRODUCTION 
 
Many epithelial surfaces in the human body are covered with a thin mucus layer. The airways, the 
entire gastrointestinal tract, and the eyes are only few of the sites where mucus can be found. 
Structurally, the mucus is a semi-permeable viscoelastic hydrogel with heterogeneous composition. 
Indeed, it consists of about 95% by water and approximately 5% by electrolytes, lipids, fragments of 
DNA (especially observed in pathological states) and different types of proteins (Creeth, 1978; Murgia 
et al., 2017). By acting as a barrier, mucus primary function is to protect the underlying epithelium 
from noxious agents, such as air pollutants or bacteria. The defensive activity of mucus can be 
principally attributed to mucins, that are the primarily expressed proteins within mucus.  
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Mucins are described as long polymeric glycoconjugates having high molecular weight (1-40 x 106 
Da, (Taherali et al., 2017)), consisting of a linear peptide backbone, rich in tandem repeats of proline, 
threonine and serine (PTS domains). To PTS domains a huge amount of carbohydrate chains (up to 
40-80% by weight) are O-linked (García-Díaz et al., 2017; Johansson et al., 2011). The bounds are 
formed between hydroxylic groups on the peptide backbone, with fragments of fucose, galactose, 
sialic acids, N-acetylglucosamine (GlcNAc) and N-acetylgalactoseamine (GalNAc) on the 
polysaccharide chains (Boegh and Nielsen, 2015). Also present, but less abundant, are the N-linked 
glycans to the N-terminus. The glycosylated and highly hydrophilic domains are separated by “naked” 
cystine rich and more hydrophobic domains that fold into globules stabilized by multiple internal 
disulfide bonds (Cone, 2009). In all the secretory mucins, domains similar to the von Willebrand 
Factor (vWF) C and D are present at the N-terminal, and likewise, at the C-terminal cysteine knot 
domains are exposed. Mucins exhibit an overall negative charge due to the free carboxylate (sialic 
acid) and sulfonate groups present in the glycosylated PTS domains. The overall negative charge 
increases the stability of the mucin network thanks to repulsive forces.  
Due to the wide variety of functional groups present into its structure, mucin can establish many 
interactions with molecules of hydrophilic or hydrophobic nature, by electrostatic and hydrogen 
bonding interactions. Lipophilic molecules can interact either with cystine rich domains or with non-
PTS regions. Similarly, drugs provided with sulfhydryl groups are capable to form stronger bonds 
(covalent bonds) with the cystine-rich domains of the naked portions of the mucin structure (Boegh 
and Nielsen, 2015), (Zanin et al., 2016) (Figure 1). 
 
 
 
Figure 1. Structure of mucin monomer and types of interactions that can be established with drugs.  
 
Since the mucin-drug interaction may have an important role on drug pharmacokinetics (as a strong 
bind with the protein may result in a reduced drug absorption, hence a low drug efficacy), in this study 
we have investigated the interaction between several drugs of interest in cystic fibrosis (CF) and 
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mucin (Figure 2). Since CF patients are susceptible to concurrent chronic pulmonary infections by 
bacteria, which gradually destroys lung tissues, one of the major goals of CF therapies involves the 
maintenance of the pulmonary function (“Cystic Fibrosis Foundation [US],” 2019). With this purpose, 
antibiotics are a standard of care for CF patients. Anti-infective therapies are employed to prevent, 
eradicate and control respiratory infections. By fighting bacterial infections, the antibiotic treatments 
lead to a reduction of the inflammatory milieu, therefore an improvement of the pulmonary function. 
One of the most recurrent and aggressive bacteria is Pseudomonas aeruginosa. If not detected and 
treated adequately, infections related to this gram-negative, opportunistic bacterium become chronic, 
which resultant inflammatory response is closely linked to decreased pulmonary function (Edmondson 
and Davies, 2016). While P. aeruginosa is the most aggressive bacteria for CF patients, other 
pathogens as Staphylococcus aureus or Burkholderia cepacia can also infect the airways, therefore 
different classes of antibiotics are employed in CF therapy. Inhaled tobramycin associated with 
aztreonam lysine is usually the first line of treatment for early infections. 
The affinity of some drugs for mucin has been previously studied using spectroscopic methods by 
Pontremoli et al (Pontremoli et al., 2015), and by chromatographic methods by Gargano et al 
(Gargano et al., 2014), whereas Barbero et al have investigated the interactions of both carbon 
nanotubes (CNTs) and gold nanoparticles (GNPs) with mucin(Barbero et al., 2018, 2016). Yet, much 
needs still to be uncover about mucin-drugs interaction and the physico-chemical parameters that 
govern the affinity of drugs for mucin. In this work, antibiotics from different anti-infective classes 
were employed to assess their interaction with mucin, including ceftazidime, and its core chemical 
structure, 7-aminocephalosporanic acid (7-ACA), aztreonam, ampicillin, tobramycin, levofloxacin and 
rifampicin. Moreover, a selective and reversible inhibitor of the transmembrane protein CFTR 
(CFTR(inh)-172) has been tested too (Thiagarajah et al., 2004).  
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Figure 2. Chemical structures and pharmaceutical class of the tested molecules 
 
2. MATERIALS AND METHODS 
 
2.1 Materials 
 
Mucin from porcine stomach (PGM type III, bound sialic acid 0.5-1.5%, partially purified powder), 
aztreonam, CFTR(inh)-172, ampicillin, tobramycin, levofloxacin, 7-ACA and rifampicin were 
purchased from Sigma Aldrich. Commercial ceftazidime for injection was supplied from Fresenius 
Kabi. PGM and drugs stock solutions for UV and fluorescence analysis were prepared in PBS 
(phosphate buffer solution 2 mM, pH = 7.4). Dissolution of the powder compounds was enhanced by 
sonication in an ultrasonic bath. The CFTR(inh)-172 stock solution was prepared by previously 
dissolution of the powder into a minimum volume of EtOH. All chemicals were of analytical reagent 
grade and were used without further purification. Millipore grade water was obtained from an in-house 
Millipore system (resistivity: 18.2 M cm at 25 °C).  
 
2.2 Methods 
 
2.2.1 UV-Vis absorption spectroscopy 
 
UV-Vis absorption spectra were measured by a UH5300 Hitachi spectrophotometer at room 
temperature, using quartz cuvettes (1 cm pathway length). The UV measurements were made in the 
range of 200-400 nm (with the exception of CFTR(inh)-172 where the range was set on 200-500 nm). 
Spectra of a 0.05 mg/mL mucin solution were recorded in the absence and in the presence of 
increasing concentrations of drugs (Figure 3. C7-ACA (a-g) = 0, 5, 10, 15, 20, 25, 30 µM; Cceftazidime (a-f) 
= 0, 5, 10, 20, 40, 60 µM; Caztreonam (a-g) = 0, 5, 10, 15, 20, 30, 40, 50 µM; Campicillin (a-g) = 0, 25, 50, 
100, 200, 500, 800 µM; CCFTR(inh)-172 (a-g) = 0, 2, 5, 7, 10, 15, 20 µM; Ctobramycin (a-h) = 0, 25, 50, 100, 
200, 500, 800, 1600 µM; Clevofloxacin (a-g) = 0, 1, 2, 3, 4, 6, 8 µM; Crifampicin (a-g) = 0, 1, 2, 4, 8, 12, 20 
µM.). 
 
2.2.2 Emission spectroscopy 
 
Fluorescence emission spectra in steady state mode were acquired at three temperatures (296, 303 and 
310 K) using a Horiba Jobin Yvon Fluorolog 3 TCSPC fluorimeter equipped with a 450-W Xenon 
lamp and a Hamamatsu R928 photomultiplier. 
Fluorescence spectra were recorded in the range of 290-480 nm and the excitation wavelength was 
fixed on 280 nm. Excitation and emission slit width was set on 6 and 7, respectively. A constant 
concentration (0.05 mg/mL) of PGM was analysed by successive increasing the concentration of the 
drugs (Figure 4. C7-ACA (a-l) = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 ,10, 12 µM; Cceftazidime (a-i) = 0, 0.5, 1, 1.5, 2, 3, 
4, 5, 6 µM; Caztreonam (a-i) = 0, 0.1, 0.5, 1, 2, 3, 4, 5, 6 µM; Campicillin (a-k) = 0, 50, 100, 150, 200, 250, 
300, 350, 400, 450, 500 µM; CCFTR(inh)-172 (a-h) = 0, 0.05, 0.1, 1, 1.5, 2, 2.5, 3 µM; Ctobramycin (a-i) = 0, 
150, 200, 500, 600, 800, 1000, 1200, 1600 µM; Clevofloxacin (a-j) = 0, 0.005, 0.01, 0.09, 0.15, 0.25, 0.5, 
1, 1.5, 2 µM; Crifampicin (a-i) = 0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5 µM.). After preparation, samples were left to 
equilibrate for at least 30 min and only then fluorescence measures were performed. 
To minimize the inner filter effect (IFE), the concentration of the different drugs was set in order to 
have absorbance values lower than 0.1. However, as reported by Arumugam et al., a change in 
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absorption equal to 0.03 corresponds to a 3% reduction in emission intensity of protein, so it is 
necessary to correct the observed emission intensity for IFE even for absorption values lower than 0.1 
(Sharma et al., 2014). The IFE correction was done for the fluorescence intensities of mucin and drug 
using the following equation: 
 
𝐹௖௢௥௥௘௖௧௘ௗ ൌ 𝐹௢௕௦௘௥௩௘ௗ ∙ 10
ሺ஺೐ೣା஺೐೘ሻଶ  ሺ1ሻ 
 
where Fcorrected and Fobserved are the corrected and observed fluorescence intensities, respectively. Aex 
and Aem are the solution absorbance at the excitation and emission wavelengths, respectively. 
 
3. RESULTS AND DISCUSSION 
 
3.1 UV-Vis absorption studies 
 
UV-Vis absorption spectroscopy is a simple and commonly employed technique for studying the 
interactions between proteins and small molecules (Sirajuddin et al., 2013; Zhang et al., 2008). By 
monitoring the changes in the absorption properties of the protein, it is possible to detect the formation 
of a complex between the protein and the small molecule. It has been assumed that a shift of the 
maximum peak of the protein in the presence of the ligand is a proof of the formation of a complex 
between the two species. Mucin has an absorption peak at 257 nm principally due to the presence of 
the amino acid phenylalanine.  
The UV-Vis absorption spectra of mucin were recorded by keeping constant the concentration of 
protein, while the concentration of drug was varied increasingly (Figure 3). Except for tobramycin 
(Figure 3-F), that have no effect at all upon mucin, the UV absorption intensity was gradually 
enhanced for PGM following the addition of increasing amounts of drug (hyperchromism). These 
changes may be explained by the formation of a new mucin-drug complex.  
 
3.2 Steady state fluorescence spectroscopy 
 
Fluorescence spectroscopy is probably one of the most commonly technique used to study interaction 
between small molecules and proteins. Normally, the fluorescence of proteins is caused only by three 
intrinsic fluorophores present in the protein, i.e. tryptophan, phenylalanine and tyrosine amino acids 
(Sirajuddin et al., 2013; Zhang et al., 2008). After excitation at 280 nm, PGM shows a strong 
fluorescence emission at 350 nm due to the presence of tryptophan residues. 
Since tryptophan fluorescence intensity is extremely sensitive to the local environment, in the present 
work, the interaction of drugs to PGM was evaluated by measuring the intrinsic fluorescence of the 
protein before and after addition of increasing concentrations of drug. It was observed that the 
fluorescence intensities of PGM was gradually reduced with increasing concentrations of ceftazidime, 
aztreonam, CFTR(inh)-172, and levofloxacin (Figure 4, graphs B, C, E, and G, respectively). It is 
possible to assume that during the binding interaction, the aforementioned drugs have altered 
tryptophan microenvironment. No significative variations of fluorescence intensities were detected in 
the presence of 7-ACA, ampicillin, tobramycin, and rifampicin (Figure 4, graphs A, D, F, and H, 
respectively). The process that decreases the intensity of the fluorescence emission is known as 
fluorescence quenching. Several processes can result in quenching, such as excited state reactions, 
energy transfer, ground-state complex formation (static quenching) and collisional quenching (also 
called dynamic quenching). Both static and dynamic quenching require molecular contact between the 
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fluorophore (mucin) and the quencher (drug). In the case of dynamic quenching, the quencher diffuses 
to the fluorophore and, upon contact, the fluorophore returns to the ground state without emission of a 
photon. On the other hand, in static quenching a non-fluorescent complex is formed between the 
fluorophore and the quencher (Lakowicz, 2006). 
 
 
 
Figure 3. UV-Vis absorption spectra of mucin (PGM, blue line) in the presence of 7-ACA (A), ceftazidime (B), aztreonam 
(C), ampicillin (D), CFTR(inh)-172 (E), tobramycin (F), levofloxacin (G), and rifampicin (H). The red dashed lines reports 
the absorption spectra of the drugs alone at a concentration that gives an absorbance of about 0.1 (7-ACA 12 µM, ceftazidime 
6 µM, aztreonam 10 µM, ampicillin 500 µM, CFTR(inh)-172 5 µM, tobramycin 1600 µM, levofloxacin 2 µM, and 
rifampicin 5 µM). 
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Figure 4. Steady state fluorescence spectra of mucin (PGM) in the presence of 7-ACA (A), ceftazidime (B), aztreonam (C), 
ampicillin (D), CFTR(inh)-172 (E), tobramycin (F), levofloxacin (G), and rifampicin (H). The red dashed lines report the 
fluorescence emission spectra of drug alone at the maximum concentration used. 
 
3.2.1 Quenching mechanism of PGM in the presence of drugs 
 
The fluorescence quenching data were analysed according to Stern-Volmer equation: 
 
𝐹଴
𝐹 ൌ 1 ൅ 𝐾ௌ௏ሾ𝑄ሿ ሺ2ሻ 
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Where F0 is the fluorescence intensity of mucin alone and F is the fluorescence of mucin in the 
presence of increasing concentrations of quencher [Q]. KSV is the Stern-Volmer quenching constant. 
[Q] is the quencher (drug) concentration. Quenching data are presented as plots of F0/F vs [Q], 
yielding an intercept of one on the y axis and a slope equal to KSV (Figure 5). 
 
 
 
Figure 5. Stern-Volmer plots of PGM - ceftazidime (B), PGM - aztreonam (C), PGM - CFTR(inh)-172 (E), and PGM – 
Levofloxacin (G). 
 
Linear Stern-Volmer plots does not prove that collisional quenching of fluorescence has occurred. 
Static and dynamic quenching can be distinguished by their differing dependence on temperature. 
Larger amounts of collisional quenching are observed at higher temperatures due to the faster 
diffusion rates, while smaller amounts of static quenching are observed at higher temperatures since 
less weakly bound complexes are formed (Lakowicz, 2006). 
The KSV of PGM – ceftazidime and PGM – CFTR(inh)-172 increases with the increasing of 
temperature (checked at 296 K, 303 K and 310 K. See Table 2), which implies a dynamic quenching 
between mucin and the aforementioned drugs. The KSV of PGM – aztreonam and PGM – levofloxacin 
is similar with negligible variations upon increasing temperature. 
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Table 2. The quenching constants of mucin (PGM) and drugs at different temperatures. 
 
 KSV (M-1) 104
 296 K 303 K 310 K 
Ceftazidime 2,5 ( 0.17) 3,7 ( 0.30) 7,0 ( 0.36) 
Aztreonam 2,6 ( 0.17) 2,3 ( 0.15) 2,5 ( 0.09) 
CFTR(inh)-172 5,4 ( 0.16) 6,1 ( 0.19) 6,9 ( 0.24) 
Levofloxacin 4,3 ( 0.20) 4,0 ( 0.16) 5,1 ( 0.46) 
 
3.2.2 Binding parameters 
 
For the determination of the association constant (KA) and the number of binding sites (n), the double 
logarithm regression curve (Equation 3) was used. 
 
𝑙𝑜𝑔 ሺ𝐹଴ െ 𝐹ሻ𝐹 ൌ 𝑙𝑜𝑔𝐾஺ ൅ 𝑛 logሾ𝑄ሿ ሺ3ሻ 
 
where F0 and F are the fluorescence intensities in absence and presence of quencher (drug), KA 
denotes the binding constant, n refers to the number of binding sites on the protein, and [Q] is the 
quencher concentration. Dissociation constant (KD) was calculated as the reciprocal of KA. From the 
plot of log[(F0-F)/F] vs log[Q] it is possible to calculate n and logKA as it represents the slope of the 
line, and its interception on the y axis, respectively. Values of n, KA and KD are reported in Table 3. 
Based on the values of n almost equal to 1, one binding site on mucin for each drug can be deduced. It 
was found that the values of KA for PGM – ceftazidime and PGM – CFTR(inh)-172 interactions 
increased with a rise in temperature, which implies a dynamic quenching. While, for PGM – 
aztreonam and PGM – levofloxacin interactions, the rise in temperature does not affect significantly 
the KA. The overall low values of KA reflect the establishment of a weak bound with mucin. 
 
Table 3: values of the number of binding sites on mucin for each mucin-drug complex (n), association (KA) and dissociation 
constant (KD). 
 
 n KA (M-1) 103 KD (M) 10-4 
Ceftazidime    
296 K 0.74 ( 0.040) 1.1 ( 0.081) 9.14 
303 K 0.73 (0.064) 1.3 ( 0.15) 7.62 
310 K 0.78 ( 0.039) 4.6 ( 0.29) 2.16 
Aztreonam    
296 K 0.64 ( 0.035) 0.32 ( 0.026) 32 
303 K 0.63 ( 0.064) 0.26 ( 0.038) 39 
310 K 0.64 ( 0.11) 0.30 ( 0.076) 34 
CFTR(inh)-172    
296 K 0.72 ( 0.049) 1.3 ( 0.12) 7.8 
303 K 0.81 ( 0.032) 5.0 ( 0.25) 2.0 
310 K 0.93 ( 0.045) 24 ( 1.5) 0.41 
Levofloxacin    
296 K 0.75 ( 0.049) 1.4 ( 0.14) 6.9 
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303 K 0.90 ( 0.098) 9.4 ( 1.4) 1.1 
310 K 0.72 ( 0,0094) 0.96 ( 0.019) 10 
 
3.2.3 Thermodynamic parameters 
 
A ligand can bind a protein basically through four types of non-covalent interactions: van der Waals 
forces, hydrogen bond, hydrophobic and electrostatic interactions. The thermodynamic parameters, 
enthalpy (H°) and entropy (S°), are used as evidence for the nature of the acting forces (Chaves et 
al., 2017). According to the data of enthalpy and entropy changes, the model of protein-drug 
interaction can be summarized as (Pontremoli et al., 2015): (i) H° > 0 and S° > 0 are indicative of 
binding driven by hydrophobic forces; (ii) H° < 0 and S° < 0 interactions through van der Waals 
interactions and hydrogen bonds; (iii) H° < 0 and S° > 0 are indicative of electrostatic interactions. 
The thermodynamic parameters were calculated through Van’t Hoff equations: 
 
න 𝐾஺ ൌ െ ∆𝐻°𝑅𝑇 ൅
∆𝑆°
𝑅  ሺ4ሻ 
 
Δ𝐺° ൌ െ𝑅𝑇 ln 𝐾஺ ሺ5ሻ 
 
ΔS° ൌ Δ𝐻° െ Δ𝐺°𝑇 ሺ6ሻ 
 
where KA is the binding constant, R is the gas constant (8.31447 J mol-1 K-1), T are the experimental 
temperatures (296 K, 303 K, 310 K) and G° corresponds to the Gibbs free energy variation. Values 
of H°, S° and G° are summarized in Table 4. As it can be observed from Table 4, for mucin – 
ceftazidime, mucin – CFTR(inh)-172 and mucin – levofloxacin complexes both H° and S° are 
positive, therefore hydrophobic interactions are the predominant driving forces for the formation of 
these protein-drug complexes. On the other hand, a positive and negative value of H° and S° 
respectively, have been found for mucin – aztreonam complex, so this implies that mostly electrostatic 
forces occur between mucin and drug. The binding process is assumed to be spontaneous as G° 
values are negative for all interactions. 
 
Table 4. Thermodynamic parameters for mucin-drug complexes at different temperatures 
 
 G (kJ mol-1) H° (kJ mol-1) S° (J mol-1 K-1) 
Ceftazidime    
296 K -24.92 
56.22 273.7 303 K -26.47 
310 K -28.76 
Aztreonam    
296 K -25.04 
-0.74 81.77 303 K -25.32 
310 K -26.20 
CFTR(inh)-172    
296 K -26.82 13.66 136.7 303 K -27.75 
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310 K -28.73 
Levofloxacin    
296 K -26.28 
8.76 117.9 303 K -26.69 
310 K -27.94 
 
It seems that an undefined relation exists between drug lipophilicity and interaction with mucin, 
particularly, hydrophobic drugs tend to interact more with mucin. As reported in Figure 6, the greater 
the logD7.4 is, the greater the KSV. Indeed, CFTR(inh)-172 that is the more lipophilic molecule at pH 
7.4 has the greater value of KSV, followed by levofloxacin with a lower value of logD7.4; aztreonam and 
ceftazidime, which are the more hydrophilic drugs at pH 7.4, have the lowest values of KSV. 
 
 
 
Figure 6. Histogram of the Stern-Volmer constants (KSV) and values of logD7.4 of drugs. Values of logD7.4 are predicted by 
means of ChemAxon. 
 
3.2.4 Resonance energy transfer 
 
One important process that can occur in the excited state is the resonance energy transfer, RET (also 
called fluorescence, or Förster, energy transfer, FRET). This process takes place whenever the 
emission spectrum of a fluorophore, called the donor, overlaps with the absorption spectrum of 
another molecule, called the acceptor. The distance between donor and acceptor, as well as the extent 
of spectral overlap, determine the amount of energy transfer (Lakowicz, 2006). The efficiency of 
energy transfer can be calculated according to Equation 7: 
 
𝐸 ൌ 1 െ ൬ 𝐹𝐹଴൰ ൌ
𝑅଴଺
𝑅଴଺ ൅ 𝑟଺ ሺ7ሻ 
 
where E can be determined experimentally from the donor (mucin) emission in the absence (F0) and 
presence of acceptor (F); r is the distance between the donor and the acceptor (drug); R0 is the critical 
distance when the efficiency of transfer is 50%. R0 can be obtained with the Equation 8: 
 
𝑅଴଺ ൌ 8.79 ∗ 10ିହሾ𝑘ଶ𝑛ସ𝜑𝐽ሺ𝜆ሻሿ ሺ8ሻ 
 
where k2 is the orientation factor, n is the refractive index of the medium,  is the fluorescence 
quantum yield of the donor, and J is the overlap integral between the fluorescence emission spectrum 
of donor and the absorption spectrum of the acceptor, and it can be obtained according to Equation 9: 
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𝐽 ൌ 𝐹ሺ𝜆ሻ𝜀ሺ𝜆ሻ𝜆
ସ∆𝜆
∑ 𝐹ሺ𝜆ሻ∆𝜆 ሺ9ሻ 
 
where F() is the fluorescence intensity of the donor at wavelength  and () is the molar absorption 
coefficient of the acceptor at wavelength . In this case k2 = 2/3, n = 1.336 and  = 0.118 (Pontremoli 
et al., 2015). 
An example, the overlaps of emission spectra of mucin and absorption spectra of aztreonam and 
tobramycin are presented in Figure 7. Values of J, E, R0 and r were determined for every interaction 
and are reported in Table 5. 
Data obtained according to the FRET theory confirm that ceftazidime, aztreonam, CFTR(inh)-172 and 
levofloxacin interact with mucin, whereas the other drugs do not form any complex with the protein. 
However, the efficiency of energy transfer (E) for the drugs able to form a mucin-drug complex is 
quite low (0.1-0.3%), while in the other cases E is almost zero. Even if resonance energy transfer 
(RET) can occur across a distance below 10 nm (Ray et al., 2014), it does not mean that a value of 
donor-to-acceptor smaller than 10 nm results in RET. Indeed, as for 7-ACA, ampicillin, tobramycin 
and rifampicin, the donor-to-acceptor value is even more than two-fold the Förster distance (R0), that 
is the distance at which the RET is efficient at 50%. Even if rifampicin has a high value of spectra 
overlap, no interaction is established as the efficiency of energy transfer is zero. 
 
 
 
Figure 7. The overlaps of emission spectra of mucin and the absorption spectra of aztreonam (A) and tobramycin (B).  
 
Table 5. Values of J, E, R0 and r of mucin-drug complexes determined according to equations 3, 4 and 5. 
 
  J (cm3 L mol-1) E (%) R0 (nm) r (nm) 
A 7-ACA 3.82  1012 0.01 3.74 8.56 
B Ceftazidime 2.99  1013 0.18 5.27 6.75 
C Aztronam 3.54  1013 0.20 5.41 6.80 
D Ampicillin 3.36  1011 0.00 2.40 9.07 
E CFTR(inh)-172 3.24 1014 0.22 7.83 9.69 
F Tobramycin 3.92  1010 0.00 1.74 4.12 
G Levofloxacin 1.76  1014 0.13 7.07 9.77 
H Rifampicin 1.52  1014 0.00 6.90 17.9 
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4. CONCLUSIONS 
 
In the present work, the interaction of mucin with some antibiotics of interest in cystic fibrosis was 
investigated at three different temperatures by two spectroscopic methods. Fluorescence quenching 
data indicate that ceftazidime, aztreonam, CFTR(inh)-172 and levofloxacin binds mucin, whereas no 
interaction is observed for 7-ACA, ampicillin, tobramycin and rifampicin. The increasing quenching 
upon increasing temperature for ceftazidime and CFTR(inh)-172 indicate a dynamic quenching 
process. The KA and n values indicate that ceftazidime, aztreonam, CFTR(inh)-172 and levofloxacin 
moderately binds to mucin and there is only one principal site of binding for this association. The low 
affinity, or absence of it as for tobramycin, toward mucin could in part explain why these antibiotics 
are widely used in CF therapies. Contrary to what was expected, the charge of the molecule seems to 
not play a fundamental role over mucin-drug interaction, in fact positively charged molecules at pH 
7.4, such as tobramycin, have no interaction, whereas negatively charged drugs such as CFTR(inh)-
172 or aztreonam can complex the protein. Indeed, the thermodynamic parameters (H° and S° > 0) 
suggest that hydrophobic forces played the major role in the binding process between mucin and 
ceftazidime, CFTR(inh)-172 and levofloxacin, while electrostatic forces may play a major role for 
mucin – aztreonam interaction. The negative value of G° implies a spontaneous binding. The 
distance between donor and acceptor was calculated according to FRET theory and resonance energy 
transfer was confirmed for ceftazidime, aztreonam, CFTR(inh)-172 and levofloxacin.  
The results herein reported may improve the knowledge about drug pharmacokinetics (absorption and 
distribution process) for drugs administered in CF therapy. However, in order to find a relation 
between the molecular structure and affinity towards mucin, further studies should be conducted, and 
a broader dataset of drugs should be investigated. 
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